Gandeeva and Moderna Enter into Cryo-EM Research Collaboration to Explore Protein Surface Structure at Atomic Resolution

Rhea-AI Summary

Gandeeva Therapeutics has announced a research collaboration with Moderna Inc. (NASDAQ: MRNA) to explore applications of its cryogenic electron microscopy (cryo-EM) technology. The collaboration aims to validate Gandeeva's unique platform for a specific Moderna target, details of which remain undisclosed. The partnership reflects Gandeeva's drive to develop innovative therapeutics by integrating AI and structural biology to target challenging protein interactions. Research payments will be made by Moderna as part of the agreement, facilitating the advancement of Gandeeva's preclinical oncology pipeline.

Positive

• Collaboration with Moderna could enhance Gandeeva's research capabilities.
• Gandeeva's innovative cryo-EM platform supports advance drug discovery.

Negative

• None.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Gandeeva Therapeutics, Inc., a precision medicine company focused on designing and developing novel therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the initiation of a research collaboration with Moderna Inc. (NASDAQ: MRNA) to explore applications of Gandeeva’s differentiated technology platform for a Moderna program.

“We are excited to begin working with Moderna on a specific application of our AI-enabled cryo-EM platform that leverages our technology infrastructure and deep experience in structural biology and medicinal chemistry,” said Sriram Subramaniam, Ph.D., Founder and CEO of Gandeeva Therapeutics. “Through our internal pipeline programs and collaborations, we are aggressively pursuing the development of first-in-class modalities in targeting difficult-to-drug protein-protein interactions.”

Under the research agreement, Gandeeva and Moderna will study and validate the application of Gandeeva’s proprietary cryo-EM platform approach for an undisclosed Moderna target. Gandeeva will receive research payments from Moderna. Additional terms of the agreement were not disclosed.

About Gandeeva Therapeutics
Gandeeva Therapeutics is a precision medicine company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada. For more information, please visit www.gandeeva.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005133/en/

Emily Wight

Communications Manager, Gandeeva Therapeutics

Emily.wight@gandeeva.com

+1 778-726-4194

Source: Gandeeva Therapeutics, Inc.

FAQ

What is the recent collaboration between Moderna and Gandeeva?

Gandeeva Therapeutics has partnered with Moderna to explore applications of its cryogenic electron microscopy technology for a specific Moderna target.

What does the collaboration with Moderna involve?

The collaboration involves studying and validating Gandeeva's proprietary cryo-EM platform in relation to a target from Moderna.

What is the significance of the cryo-EM technology in drug development?

Cryo-EM technology aids in the development of therapeutics by providing insights into protein interactions that are difficult to target.

Is the financial agreement between Gandeeva and Moderna disclosed?

While Gandeeva will receive research payments from Moderna, additional terms of the agreement have not been disclosed.

How does Gandeeva's platform contribute to oncology research?

Gandeeva's platform includes innovative methods targeting key protein-protein interactions, crucial for developing new oncology therapeutics.